College of Veterinary Medicine

People in WSU Veterinary Medicine

Michael H. Court   

Michael Court
Michael H. Court, B.V.Sc., Ph.D.,
Diplomate, American College of Veterinary Anesthesiologists
Professor and William R. Jones Endowed Chair



B.V.Sc. Hons., Queensland University (1981)
Internship - Small Animal, University of Sydney (1982)
Residency - Anesthesia, Tufts University (1985)
Fellowship - Pharmacology, Flinders University (1999)
Ph.D. - Pharmacology and Experimental Therapeutics, Tufts University (2000)

Research Interests

My laboratory primarily conducts pharmacogenomic research, including studies designed to identify genetic variants and related mechanisms that determine interindividual differences in drug effect (both beneficial and adverse).  The long-term goal of our work is to translate these findings into clinical practice and improve the treatment of important diseases through pharmacogenomic-guided selection of the most effective and safest drug and drug dose for the individual patient (individualized therapeutics).  One of the main projects in our laboratory is attempting to understand the molecular and genetic basis for increased sensitivity of some sighthound dog breeds (such as greyhounds) to certain injectable anesthetic agents.  Another major project involves identifying and characterizing microRNAs that determine interindividual variability in drug glucuronidation in human liver.


Shrestha B, Reed JM, Starks PT, Kaufman GE, Goldstone JV, Roelke ME, O'Brien SJ, Koepfli KP, Frank LG, Court MH. Evolution of a major drug metabolizing enzyme defect in the domestic cat and other felidae: Phylogenetic timing and the role of hypercarnivory. PLoS One. 2011 Mar 28;6(3):e18046.

Kwara A, Lartey M, Sagoe KW, Court MH. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS. 2011 Jan 28;25(3):388-90.

Mosher CM, Court MH. Comparative and veterinary pharmacogenomics. Handb Exp Pharmacol. 2010;199:49-77.

Oleson L, von Moltke LL, Greenblatt DJ, Court MH. Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism. Xenobiotica. 2010 Feb;40(2):146-62.

He X, Hesse LM, Hazarika S, Masse G, Harmatz JS, Greenblatt DJ, Court MH. Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion.  Br J Clin Pharmacol. 2009 Nov;68(5):721-30.

Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.  AIDS. 2009 Oct 23;23(16):2101-6.

Kwara A, Lartey M, Boamah I, Rezk NL, Oliver-Commey J, Kenu E, Kashuba AD, Court MH. Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV-Coinfected Ghanaian Patients: UGT2B7*1c Is Associated With Faster Zidovudine Clearance and Glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.

Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH. CYP2B6 (c.516G>T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol. 2009 Apr;67(4):427-36.

Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, Court MH: UDP-glucuronosyltransferase (UGT) 1A6 pharmacogenetics: 1.  Identification of polymorphisms in the 5’-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. J Pharmacol Exp Ther. 2005 Mar; 313(3):1331-1339.

Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, Court MH: UDP-glucuronosyltransferase (UGT) 1A6 pharmacogenetics: 2. Structure-function studies of recombinant UGT1A6 amino acid variants. J Pharmacol Exp Ther. 2005 Mar; 313(3):1340-1346.

Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al-Rohaimi A, Von Moltke LL, Greenblatt DJ: UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther. 2004 Aug;310(2):656-65.

Hay Kraus BL, Greenblatt DJ, Venkatakrishnan K, Court MH:  Evidence for propofol hydroxylation by cytochrome P450 2B11 in canine liver microsomes: Dog breed and gender differences.  Xenobiotica 30(6):575-588, 2000.

Court MH and Greenblatt DJ:  Molecular genetic basis for deficient glucuronidation of acetaminophen in cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms Pharmacogenetics 10:355-369, 2000.

Court MH, Hay Kraus BL, Hill DW, Kind AJ and Greenblatt DJ:  Propofol hydroxylation by dog liver microsomes: Assay development and dog breed differences. Drug Metabolism and Disposition 27(11):1293-1299, 1999.

Court MH:  Anesthesia of the sighthound. Clinical Techniques in Small Animal Practice 14(1): 38-43, 1999.

Last Edited: Oct 08, 2012 9:33 AM   

Veterinary Clinical Sciences, PO Box 646610, Washington State University, Pullman WA 99164-6610, 509-335-0738, Contact Us  Safety Links